24085-03-8

Basic information

• Product Name: alpha-[(benzyl-tert-butylamino)methyl]-m-xylene-4,alpha,alpha'-triol
• Synonyms: alpha-[(benzyl-tert-butylamino)methyl]-m-xylene-4,alpha,alpha'-triol;2-[BENZYL(TERT-BUTYL)AMINO]-1-(ALPHA,4-DIHYDROXY-M-TOLYL)ETHANOL;ALPHA1-{[tert-Butyl-(phenylmethyl)-amino]-methyl}-4-hydroxy-1,3-benzenedime;α-[1,1-Dimethylethyl(phenylmethyl)aminomethyl]-4-hydroxy-1,3-benzenedimethanol;1-(4'-Hydroxy-3'-hydroxymethylphenyl)-2-(benzyl-tert-butylamino)ethanol;Ccris 3458;Einecs 246-013-7;4-(2-(Benzyl(tert-butyl)aMino)-1-hydroxyethyl)-2-(hydroxyMethyl)phenol
• CAS NO: 24085-03-8
• Molecular Formula: C₂₀H₂₇NO₃
• Molecular Weight: 329.43328
• EINECS: 246-013-7
• Product Categories: Amines;Aromatics;Impurities;Intermediates & Fine Chemicals;Pharmaceuticals
• Mol File: 24085-03-8.mol
• Article Data: 5

Chemical Properties

• Boiling Point: 496.0±33.0 °C(Predicted)
• Appearance: /
• Density: 1.162±0.06 g/cm3(Predicted)
• PKA: 9.95±0.31(Predicted)
• CAS DataBase Reference: alpha-[(benzyl-tert-butylamino)methyl]-m-xylene-4,alpha,alpha'-triol(CAS DataBase Reference)
• NIST Chemistry Reference: alpha-[(benzyl-tert-butylamino)methyl]-m-xylene-4,alpha,alpha'-triol(24085-03-8)
• EPA Substance Registry System: alpha-[(benzyl-tert-butylamino)methyl]-m-xylene-4,alpha,alpha'-triol(24085-03-8)

Safety Data

• Hazardous Substances Data: 24085-03-8(Hazardous Substances Data)

Usage

Description

alpha-[(benzyl-tert-butylamino)methyl]-m-xylene-4,alpha,alpha'-triol is an organic compound characterized by its unique molecular structure, which features a benzyl-tert-butylamino group attached to a m-xylene core with three hydroxyl groups at the 4 and alpha positions. alpha-[(benzyl-tert-butylamino)methyl]-m-xylene-4,alpha,alpha'-triol is known for its potential applications in various industries due to its distinct chemical properties.

Uses

1. Pharmaceutical Industry:
alpha-[(benzyl-tert-butylamino)methyl]-m-xylene-4,alpha,alpha'-triol is used as an impurity in the manufacturing of Albuterol sulfate (A514500) (Salbutamol sulfate) bulk drug. Its presence, although as an impurity, may contribute to the overall effectiveness and pharmacological properties of the final drug product.
2. Chemical Research and Development:
Due to its unique molecular structure, alpha-[(benzyl-tert-butylamino)methyl]-m-xylene-4,alpha,alpha'-triol can be used as a starting material or intermediate in the synthesis of other complex organic compounds. This makes it valuable in the field of chemical research and development for creating new molecules with potential applications in various industries.
3. Material Science:
The distinct chemical properties of alpha-[(benzyl-tert-butylamino)methyl]-m-xylene-4,alpha,alpha'-triol may also find applications in material science, where it could be used to develop new materials with specific properties, such as improved stability, reactivity, or selectivity in various chemical processes.

Upstream product

• 64092-10-0 N-benzylsalbutamone 
• 18559-94-9 Salbutamol 
• 100-44-7 benzyl chloride 

Downstream Products

• 18559-94-9 Salbutamol 
• 18910-68-4 2-(tert-butylamino)-1-(4-hydroxyl-3-methylphenyl)ethanol 
• 35459-11-1 acetate salt of salbutamol 

Relevant articles and documents

Preparation method of salbutamol sulfate intermediate

The invention provides a preparation method of a salbutamol sulfate intermediate. Salbutamol is a beta receptor stimulant; a current preparation technology of the salbutamol mainly takes an original research technology as a main part; the original research technology takes p-hydroxyacetophenone as a starting material and the salbutamol is prepared through chloromethylation, esterification, bromination, amination, hydrolysis and reduction. An existing synthesis method of the salbutamol sulfate intermediate is used for synthesizing through a plurality of steps and is complicated to operate; theloss of products in a preparation process is great and the technological time is relatively long. The preparation method of the salbutamol sulfate intermediate, provided by the invention, comprises the following steps: reducing carbonyl of a compound I under the action of a reducing agent to obtain a compound II; then adding a debenzylation reagent and carrying out debenzylation reaction to obtainthe salbutamol sulfate intermediate III. According to the preparation method, the salbutamol sulfate intermediate III is prepared from the compound I by adopting a 'one-pot method'; operation steps are reduced, the reaction time is shortened and the reaction yield is improved.

Synthesis, isolation and characterization of process-related impurities in salbutamol sulphate

Three known and one unknown impurities in salbutamol sulphate bulk drug at level 0.1% (ranging from 0.05-0.1%) were detected by gradient reverse phase high performance liquid chromatography. These impurities were preliminarily identified by the mass number of the impurities. Different experiments were conducted and finally synthesized and characterized the known and unknown imputities. Copyright E-Journal of Chemistry 2004-2011.

Saligenin analogs of sympathomimetic catecholamines.

-